Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil; J. Han; L. Wang; J. Vissing; B. van Engelen; J. Statland; M. Mellion; J. Shoskes; C. Morabito; J. Jiang; J. Webster

doi:10.1016/j.nmd.2022.07.258

Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil, J. Han, L. Wang, J. Vissing, B. van Engelen, J. Statland, M. Mellion, J. Shoskes, C. Morabito, J. Jiang, J. Webster

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	P.136
Tidsskrift	Neuromuscular Disorders
Vol/bind	32
Udgave nummer	Supplement 1
Sider (fra-til)	S104-S104
Antal sider	1
ISSN	0960-8966
DOI	https://doi.org/10.1016/j.nmd.2022.07.258
Status	Udgivet - 2022
Begivenhed	27th International Congress of the World-Muscle-Society (WMS) - Halifax, Canada Varighed: 11 okt. 2022 → 15 okt. 2022

Konference

Konference	27th International Congress of the World-Muscle-Society (WMS)
Land/Område	Canada
By	Halifax
Periode	11/10/2022 → 15/10/2022

Adgang til dokumentet

10.1016/j.nmd.2022.07.258

Citationsformater

Tawil, R., Han, J., Wang, L., Vissing, J., van Engelen, B., Statland, J., Mellion, M., Shoskes, J., Morabito, C., Jiang, J., & Webster, J. (2022). Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD. Neuromuscular Disorders, 32(Supplement 1), S104-S104. [P.136 ]. https://doi.org/10.1016/j.nmd.2022.07.258

Design of Reach : Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD. / Tawil, R.; Han, J.; Wang, L.; Vissing, J.; van Engelen, B.; Statland, J.; Mellion, M.; Shoskes, J.; Morabito, C.; Jiang, J.; Webster, J.

I: Neuromuscular Disorders, Bind 32, Nr. Supplement 1, P.136 , 2022, s. S104-S104.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Tawil, R, Han, J, Wang, L, Vissing, J, van Engelen, B, Statland, J, Mellion, M, Shoskes, J, Morabito, C, Jiang, J & Webster, J 2022, 'Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD', Neuromuscular Disorders, bind 32, nr. Supplement 1, P.136 , s. S104-S104. https://doi.org/10.1016/j.nmd.2022.07.258

@article{9cb316a3db884cf5b7dcddf6a1804daa,

title = "Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD",

author = "R. Tawil and J. Han and L. Wang and J. Vissing and {van Engelen}, B. and J. Statland and M. Mellion and J. Shoskes and C. Morabito and J. Jiang and J. Webster",

year = "2022",

doi = "10.1016/j.nmd.2022.07.258",

language = "English",

volume = "32",

pages = "S104--S104",

journal = "Journal of Neuromuscular Diseases",

issn = "0960-8966",

publisher = "Elsevier",

number = "Supplement 1",

note = "27th International Congress of the World-Muscle-Society (WMS) ; Conference date: 11-10-2022 Through 15-10-2022",

}

TY - ABST

T1 - Design of Reach

T2 - 27th International Congress of the World-Muscle-Society (WMS)

AU - Tawil, R.

AU - Han, J.

AU - Wang, L.

AU - Vissing, J.

AU - van Engelen, B.

AU - Statland, J.

AU - Mellion, M.

AU - Shoskes, J.

AU - Morabito, C.

AU - Jiang, J.

AU - Webster, J.

PY - 2022

Y1 - 2022

U2 - 10.1016/j.nmd.2022.07.258

DO - 10.1016/j.nmd.2022.07.258

M3 - Conference abstract in journal

VL - 32

SP - S104-S104

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 0960-8966

IS - Supplement 1

M1 - P.136

Y2 - 11 October 2022 through 15 October 2022

ER -